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This interactive feature addresses the approach to a clinical issue. A case vignette is followed by specific options, neither of which 
can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. Readers can 
participate in forming community opinion by choosing one of the options and, if they like, providing their reasons.
C ase Vignet te
An Outbreak of Meningococcal 
Disease
Ken Wu, M.B., B.S.
You are a physician advising the national health 
agency in your country (comparable to the Cen-
ters for Disease Control and Prevention [CDC] in 
the United States). An outbreak of meningitis 
has occurred among students in a public univer-
sity. Four cases of invasive meningococcal dis-
ease caused by Neisseria meningitidis serogroup B 
have been reported to the national health agency 
within the past month. All the affected patients 
were undergraduate students between 19 and 21 
years of age who were otherwise healthy. They 
had had all the routine childhood immunizations 
recommended by the national health agency but 
were not immunized against meningococcal B. 
All four patients were hospitalized and treated 
successfully and had no permanent complica-
tions. Reports of the outbreak have made local 
and national news and are trending on social 
media, causing a high level of anxiety among 
parents, especially those with children graduat-
ing from high school.
In the United States, there have been 10 univer-
sity-based outbreaks of meningococcal B disease 
in seven states since 2013; these outbreaks have 
involved a total of 39 cases and 2 deaths.1 In 
response, affected universities have initiated 
meningococcal B vaccination campaigns, with 
mass vaccination of university students recom-
mended in 8 of the outbreaks. Since its develop-
ment, the vaccine against meningococcal B has 
become part of the routine immunization sched-
ule in some jurisdictions; for example, it is in-
cluded in the routine immunization schedule in 
the United Kingdom for all infants younger than 
1 year of age and in the Australian state of South 
Australia for all infants younger than 1 year of 
age and for adolescents 16 to 17 years of age.2,3 
The current policy of the health agency in your 
country regarding administration of the menin-
gococcal B vaccine to adolescents and young 
adults 16 to 23 years of age who are not at in-
creased risk is that the decision about vaccina-
tion should be based on individual clinical factors.
Your national health agency is asking for your 
advice about whether to expand immunization 
for meningococcal B by recommending admin-
istration of the vaccine to all persons 17 to 18 
years old in addition to a mass vaccination cam-
paign at universities at which there is an out-
break. In particular, you are asked to consider 
the effectiveness of the vaccine in preventing 
both meningococcal B disease and transmission 
of infection, as well as the cost-effectiveness of 
a mass vaccination program.
Treatment Op tions
Which one of the following choices would you 
recommend to the national health agency? Base 
your choice on the published literature, your 
own experience, published guidelines, and other 
information sources.
1. Administer the meningococcal B vaccine to all 
17-to-18-year-olds and to all students at uni-
versities with an outbreak.
2. Administer the meningococcal B vaccine only 
to students at universities with an outbreak.
To aid in your decision making, each of these 
approaches is defended in a short essay by an 
expert in the field. Given your knowledge of the 
issue and the points made by the experts, which 
approach would you choose?
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Op tion 1
Administer the Meningococcal B 
Vaccine to All 17-to-18-Year-Olds 
and to All Students at Universities 
with an Outbreak
E. Kim Mulholland, M.D.
Meningococcal B disease is a curious and terrify-
ing condition with unusual epidemiology. Spo-
radic cases occur throughout the world, with 
occasional small outbreaks, but large-scale epi-
demics, when they occur, can last for a decade or 
more. Unlike other meningococcal serogroups, 
meningococcal B is not amenable to the highly 
successful vaccine-development approach that is 
based on covalent binding of the capsular poly-
saccharide to a carrier protein to form a poly-
saccharide–protein conjugate vaccine. Vaccines 
developed in the Americas and in Norway in 
response to previous meningococcal B epidem-
ics were based on the outer-membrane vesicle 
approach using vesicles of the bacterial mem-
brane that express important epitopes, particu-
larly the immunodominant PorA protein, which 
varies from epidemic to epidemic.4 The 1990–
2005 epidemic in New Zealand was success-
fully aborted by a tailor-made outer-membrane 
vesicle vaccine, which was administered to a 
high proportion of persons younger than 20 
years of age in the country.5 That vaccine has 
since been modified to produce one of the two 
currently available vaccines that cover most 
strains of meningococcal B — 4CMenB (Bex-
sero, GlaxoSmithKline). The other meningo-
coccal B vaccine currently in use is MenB-FHbp 
(Trumenba, Pfizer) which targets factor H bind-
ing protein.
Although meningococcal B disease can affect 
all ages, the two age groups at highest risk are 
young infants and older teenagers. The organ-
ism circulates easily in the 17-to-18-year-old age 
group because of the ease with which persons of 
this age share saliva6 — a point that may be well 
understood by readers who are parents of teen-
agers or those with fond memories of those 
years. Sadly, this behavior carries with it a small 
risk of the horrors of meningococcal B disease, 
which often leads to serious sequelae, such as 
multiple limb amputations, or to death.7 It is 
also believed to be the means by which menin-
gococcal B circulates in a community; therefore, 
prevention of carriage in this age group should 
lead to herd immunity. Unfortunately, findings 
of a large study by Marshall et al. published in 
this issue of the Journal provide convincing evi-
dence that the 4CMenB vaccine does not prevent 
carriage,6 so the objective of vaccination is to 
prevent cases. Public attention tends to focus on 
outbreaks among university students, who ac-
count for most cases of meningococcal B disease 
among young adults in the United States. How-
ever, cases also occur among the 62% of 18-to-
24-year-olds in the United States who are not 
attending university.8
There are two general approaches to vaccine 
control of meningococcal B disease. In 2015, the 
U.K. government began a national infant vacci-
nation program with 4CMenB, with the aim of 
providing direct protection to one of the age 
groups at highest risk.9 The report by Ladhani 
et al., the results of which are also published in 
this issue of the Journal, highlights the effective-
ness of that program, which is consistent with 
the experience in New Zealand.5,10 Others have 
focused attention on teenagers, the age group 
producing the highest numbers of meningococ-
cal B cases. In the United States, limiting vac-
cination to students attending universities that 
have reported cases may seem logical. The risk 
in this group may be higher, but in fact all young 
adults are at risk. Therefore, the most logical 
approach to preventing meningococcal B disease 
among students is to provide a vaccine for all 
citizens in the very-high-risk age group of 17 to 
18 years, which happens to be the usual age at 
which students enter university — and a time 
that for many students includes their first dating 
experience. In addition, students of all ages at-
tending universities in which cases have oc-
curred should be offered the vaccine and encour-
aged to accept it.
Disclosure forms provided by the author are available at 
NEJM.org.
From Murdoch Children’s Research Institute and the University 
of Melbourne Department of Paediatrics, Melbourne, VIC, Aus-
tralia; and the London School of Hygiene and Tropical Medi-
cine, London. 
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Op tion 2
Administer the Meningococcal B 
Vaccine Only to Students  
at Universities with an Outbreak
Kathryn M. Edwards, M.D.
The recommendation to administer meningococ-
cal B vaccine only to students at universities 
where an outbreak has occurred is the best ap-
proach for several reasons. First, rates of menin-
gococcal B disease are very low in the United 
States; the average annual incidence is only 0.17 
cases per 100,000 population. Among the 1174 
total cases of meningococcal disease reported 
during 2014–2016, only 166 occurred in persons 
18 to 24 years of age, and only 88 of those cases 
were due to serogroup B.11 Thus, the costs of 
immunizing an entire birth cohort of 4 million 
people with two doses of meningococcal B vac-
cine to prevent these few cases would be exces-
sive. A recent study showed that the incremental 
cost per quality-adjusted life year gained with 
universal meningococcal B vaccination approached 
nearly $14 million, as compared with the usual 
willingness-to-pay benchmark threshold of 
$150,000 per quality-adjusted life year.12
The second reason that only targeted immu-
nization during an outbreak is preferable is sup-
ported by the study by Marshall et al. published 
in this issue of the Journal.6 Investigators from 
Australia immunized more than 20,000 15-to-
18-year-old students with two doses of meningo-
coccal B vaccines and showed that vaccination 
was not associated with a reduction in carriage 
— a finding that contrasts with the effect of the 
conjugate vaccines targeting serogroups A, C, W, 
and Y, which prevent colonization. Immuniza-
tion with meningococcal B vaccine does not 
prevent transmission and does not generate herd 
immunity.
Meningococcal B vaccines are directed against 
proteins expressed on meningococcal B strains, 
in contrast to the serogroup A, C, W, and Y vac-
cines, which are directed against the polysac-
charide capsules. Thus, not all infecting strains 
of serogroup B organisms share these proteins, 
and it is difficult to predict whether the vaccine 
strains will match the circulating strains. Data 
from one outbreak showed that more than 30% 
of participants who were vaccinated with two 
doses of meningococcal B vaccine had low anti-
body titers, and therefore, there was no evidence 
of a protective response against the outbreak 
strain.13 The study conducted in England by Lad-
hani et al. shows that vaccine effectiveness for 
the prevention of invasive MenB disease in infants 
with a universal immunization program was 
only 60%, with wide confidence intervals.10 Data 
on vaccine effectiveness from a large outbreak in 
Quebec, where more than 80% of nearly 60,000 
older persons were immunized, showed similar 
rates.14 In addition, reports of vaccine failures in 
fully immunized adolescents during outbreaks 
supports the notion that the effectiveness of this 
vaccine falls short of that of other vaccines, such 
as measles or bacterial conjugate vaccines.15
Finally, rapid waning of vaccine-induced im-
munity has been clearly shown in serologic stud-
ies,16 a finding that has led to the recent recom-
mendation by the CDC Advisory Committee on 
Immunization Practices that persons at high risk 
for meningococcal serogroup B disease should 
be given a booster dose of vaccine at 1 year after 
the primary series. Even if the entire birth co-
hort were immunized with meningococcal B 
vaccine, immunity for longer than a year could 
not be ensured.
Thus, for all the reasons outlined above, the 
best approach is to immunize only the students 
enrolled at the university with the outbreak. 
With robust use of the media to publicize the 
need for vaccination and with multiple partici-
pating clinics, the vaccine can be delivered to a 
large percentage of the university community.
Disclosure forms provided by the author are available at 
NEJM.org.
From the Division of Pediatric Infectious Diseases, Department 
of Pediatrics, Vanderbilt University Medical Center, Nashville.
This article was updated on February 20, 2020, at NEJM.org. 
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